BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$0.88 per share, beating estimates of -$0.94 by $0.06. The company also reported revenue of $116,630,000, beating estimates of $62,676,409 by $53,953,591.
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA Insider Trading Activity
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
- GENETIC DISORDER L.P. KKR sold 6,000,000 shares for an estimated $197,760,000
- GLOBAL INVESTORS LP VIKING sold 3,065,616 shares for an estimated $106,989,998
- NEIL KUMAR (Chief Executive Officer) has made 0 purchases and 11 sales selling 883,932 shares for an estimated $31,383,439.
- BRIAN C STEPHENSON (CFO and Treasurer) has made 0 purchases and 5 sales selling 84,804 shares for an estimated $2,992,985.
- ANDREA ELLIS has made 0 purchases and 2 sales selling 40,000 shares for an estimated $1,371,500.
- HANNAH VALANTINE sold 12,875 shares for an estimated $419,499
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BRIDGEBIO PHARMA Hedge Fund Activity
We have seen 151 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FARALLON CAPITAL MANAGEMENT LLC added 2,448,000 shares (+140.1%) to their portfolio in Q4 2024, for an estimated $67,173,120
- CITADEL ADVISORS LLC removed 1,686,753 shares (-57.3%) from their portfolio in Q4 2024, for an estimated $46,284,502
- WOODLINE PARTNERS LP added 1,261,772 shares (+132.9%) to their portfolio in Q4 2024, for an estimated $34,623,023
- ASSENAGON ASSET MANAGEMENT S.A. added 1,096,799 shares (+4544.6%) to their portfolio in Q1 2025, for an estimated $37,916,341
- PICTET ASSET MANAGEMENT HOLDING SA removed 995,585 shares (-35.5%) from their portfolio in Q4 2024, for an estimated $27,318,852
- ALYESKA INVESTMENT GROUP, L.P. added 940,415 shares (+inf%) to their portfolio in Q4 2024, for an estimated $25,804,987
- JPMORGAN CHASE & CO removed 916,902 shares (-75.4%) from their portfolio in Q4 2024, for an estimated $25,159,790
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
